Clinical Trials Archive
Below is a comprehensive list of past trials the CVC has participated in. Information on current CVC trials can be found here.
| Trial Name | Theraputic Area/Study Type | Study Phase | Study Period | Study Description | ClinicalTrials.Gov Identifier |
|---|---|---|---|---|---|
| ADVANCE-MI | Myocardial Infarction | Phase 3 | 2003 | Addressing the value of primary angioplasty after combination therapy or eptifibatide monotherapy in acute myocardial infarction | N/A |
| AEGIS | Acute Myocardial Infarction | Phase 2 | 2014 - 2016 | This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI). | NCT02108262 |
| AEGIS-II | Acute Coronary Syndrome | Phase 3 | 2017 - 2024 | This is a Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome. | NCT03473223 |
| APEX-AMI | Acute Myocardial Infarction | Phase 3 | 2004 - 2007 | In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days. | NCT00091637 |
| APPLAUD | Myocardial Infarction, Unstable Angina, TIA or Stroke | Phase 2 | 1997 - 1998 | A 12-Week Double-Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Platelet Aggregation of a Dose Range of SB 214857 When Added to Aspirin in Patients with Myocardial Infarction, Unstable Angina, Transient Ischemic Attack or Stroke | N/A |
| ASCEND-HF | Heart Decompensation | Phase 3 | 2007 - 2011 | The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer. | NCT00475852 |
| ASSENT-2 | Acute Myocardial Infarction | Phase 3 | 1997 - 1999 | Assessment of the Safety and Efficacy of A New Thrombolytic Agent | N/A |
| ASSENT-3 | Myocardial Infarction | Phase 3 | 2000 - 2001 | Open-label international, multicentre, randomized, controlled trial in patients with acute ST-elevation myocardial infarction who present within 6 hours of symptom onset. Three different TNK-tPA based fibrinolytic regimens are being investigated. | N/A |
| ASSENT-3 Plus | Myocardial Infarction | Phase 3 | 2000 - 2002 | The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with enoxaparin (ENOX, group B). An additional objective in ASSENT 3 Plus was to describe the different time intervals in the prehospital phase. | NCT02181998 |
| ASSENT-4 PCI | Myocardial Infarction | Phase 4 | 2003 - 2006 | To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone. | NCT00168792 |
| BLAST-AHF | Acute Decompensated Heart Failure | Phase 2 | 2013 - 2016 | To evaluate the overall safety and efficacy of TRV027 when administered in addition to standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients hospitalized with Acute Decompensated Heart Failure (ADHF). | NCT01966601 |
| CAPTORS | Acute Myocardial Infarction | Phase 2 | 1997 - 1999 | The Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS) was a dose-finding study of staphylokinase variant SAK42D to evaluate the efficacy of the compound in patients with acute ST-segment myocardial infarction. The trial was conducted at 5 sites in Canada and 1 site in Belgium. Eighty two patients were enrolled in the study | N/A |
| CAPTORS II | Acute Myocardial Infarction | Phase 2 | 2000 - 2001 | Patients with ST elevation acute myocardial infarction, who receive either accelerated tPA as control or bolus doses of PEGylated staphylokinase (PEG-SAK). This study is a blinded, dose-ranging comparative clinical trial with a 60 minute angiographic endpoint. | N/A |
| COMMA (CARDINAL) | Acute Myocardial Infarction | 1999 - 2002 | Whether treatment of Acute Myocardial infarction within 6 hours of onset of symptoms with a bolus of h5G1.1-scFv and PTCA or bolus and infusion h5G1.1-scFv with PTCA therapy is superior to PTCA repusion theapy alone in decreasing infarct size | N/A | |
| COMPLY (CARDINAL) | Acute Myocardial Infarction | 1999 - 2002 | Whether treatment of Acute Myocardial infarction within 6 hours of onset of symptoms with a bolus of h5G1.1-scFv and thrombolytic therapy or bolus and infusion h5G1.1-scFv with thrombolytic therapy is superior to PTCA repusion theapy alone in decreasing infarct size | N/A | |
| EARLY ACS | Acute Coronary Syndrome, Myocardial Ischemia | Phase 3 | 2004 - 2008 | The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). | NCT00089895 |
| EMPACT-MI | Acute Coronary Syndrome & Heart Failure | Phase 3 | 2020 - 2024 | This is a streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of empagliflozin on hospitalisation for heart failure and mortality in patients with acute myocardial infarction | NCT04509674 |
| ERASE-MI | Myocardial Infarction | Phase 2 | 2007 - 2008 | Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI) | NCT00546260 |
| EXSCEL | Type 2 Diabetes Mellitus | Phase 3 | 2010 - 2017 | This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke. | NCT01144338 |
| FEAST-HF | Heart Failure | Investigator Initiated | 2017-2023 | This study is a single-centre clinical trial in ambulatory patients with chronic HF to evaluate whether dietary supplementation with acacia gum reduces HF-related biomarkers NT-proBNP and ST2 and how the gut microbiome responds to dietary supplementation with acacia gum. | NCT03409926 |
| FINESSE | Myocardial Infarction | Phase 3 | 2002 - 2008 | The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention. | NCT00046228 |
| GALILEO | Transcatheter Aortic Valve Replacement | Phase 3 | 2015 - 2018 | To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). | NCT02556203 |
| GUIDE-IT | Heart Failure | N/A | 2012 - 2016 | Determine the efficacy of a strategy of biomarker-guided therapy compared with usual care in high risk patients with left ventricular systolic dysfunction. | NCT01685840 |
| GUSTO | Acute Myocardial Infarction | Phase 3 | 1990 - 1993 | Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries | N/A |
| GUSTO-IIA | Acute Myocardial Infarction | Phase 3 | 1993 - 1994 | Global Use of Strategies to Open Occluded Arteries | N/A |
| GUSTO-IIB | Acute Myocardial Infarction | Phase 3 | 1993 | Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes | N/A |
| GUSTO-III | Acute Myocardial Infarction | Phase 3 | 1995 - 1997 | Global Use of Strategies to Open Occluded Coronary Arteries | N/A |
| GUSTO-IV ACS | Myocardial Infarction | Phase 3 | 1998 - 2001 | The primary objective is to compare ReoPro given as a bolus followed by a 24 hour infusion, ReoPro given as a bolus followed by a 48 hour infusion and placebo on the composite endpoint of death and myocardial infarction within 30 days of randomization in patients with acute coronary syndrome without ST segment elevation. | N/A |
| GUSTO-IV AMI | Myocardial Infarction | Phase 3 | 1999 - 2001 | MulticentreTrial in the treatment of Acute Myocardial Infarction. Patients are randomized to either a combination of half-dose r-PA and ReoPro together with low dose weight adjusted heparin or full-dose r-PA with standard heparin | N/A |
| GUSTO-V | Acute Myocardial Infarction | Phase 3 | 1999 - 2002 | Phase lll, randomized, open-label Trial evaluating the efficacy and safety of ReoPro (Abciximab) in combination with reduced dose Retavase/Rapilysin for the treatment of myocardial infarction | N/A |
| HEART-FID | Heart Failure | Phase 3 | 2017 - 2023 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (Ferric Carboxymaltose) as treatment for heart failure with iron deficiency. | NCT00121446 |
| HERO-II | Acute Myocardial Infarction | Phase 3 | 1997 - 1999 | Hirulog Early Reperfusion Occlusion | N/A |
| HiLo-HF Pilot | Heart Failure | N/A | 2017 - 2018 | The primary objective of this pilot trial is to determine whether inpatients presenting to the Emergency Department (ED) with symptoms suggestive of Acute Heart Failure (AHF), who receive supplemental oxygen adjusted at either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%) oxygen saturation level, leads to greater reduction in N-terminal-proBNP (NT-proBNP) at 72 hours. | NCT02518828 |
| HiLo-HF Registry | Acute Heart Failure | Observational | 2016 - 2019 | The HILO-HF Registry is a single centre registry that will be performed to provide information on the usual baseline oxygen saturation (SpO2) in patients presenting to ED with a primary ED diagnosis of AHF | NCT03110042 |
| IMPROVE-IT | Hypercholesterolemia Myocardial Infarction | Phase 3 | 2005 - 2014 | This is a randomized, active-control, double-blind study of subjects with stabilized high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin Combination 10/40 (single tablet, under the brand VYTORIN in the United States) compared with Simvastatin 40 mg. As per the original protocol, if low-density lipoprotein cholesterol (LDL-C) response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped). Clinical benefit will be defined as the reduction in the risk of the occurrence of the composite endpoint of cardiovascular (CV) death, major coronary events, and stroke. | NCT00202878 |
| INNOVATE-PCI | Percutaneous Coronary Intervention | Phase 2 | 2008 - 2010 | This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128. | NCT00751231 |
| LEVO-CTS | Coronary Artery Bypass Grafting Mitral Valve Surgery Low Cardiac Output Syndrome | Phase 3 | 2014 - 2016 | A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB). | NCT02025621 |
| MAP-AHF | Heart Failure | Investigator Initiated | 2019 - 2024 | The MRI Assessment of Pulmonary Edema in Acute Heart Failure (MAP-HF) trial utilizes MRI imaging to assess lung water density. The study has three objectives - (1) Measure the magnitude of increased LWD in acute HF; (2) Measure the changes in LWD with standard therapy; and (3) Determine the prognostic value of increased LWD. | NCT03999138 |
| MOIST | Acute and recovered COVID-19 | Observational | 2020 - 2022 | The MOIST Study will assess the presence, extent and time course of inflammation in the heart, lungs, brain and liver of participants with new or recent COVID-19 infection. | NCT04525404 |
| OCEANIC-AF | Atrial Fibrillation | Phase 3 | 2021 - 2024 | A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke. | NCT05643573 |
| ODYSSEY Outcomes | Atherosclerotic Cardiovascular Disease | Phase 3 | 2012 - 2018 | The study investigators have developed new techniques in Magnetic Resonance Imaging (MRI) to scan the lungs, heart, brain and liver. The study investigators hope to learn more about how the virus causes inflammation in these organs and how this inflammation changes over time as people recover from COVID-19 illness. | NCT01663402 |
| PACTS | Acute Coronary Syndromes | Phase 3 | 1997 - 1999 | The study aims to enroll 228 people in Alberta. Participants will undergo one or more MRI scans and have blood testing at one or more time points to assess for inflammation, kidney function, liver function and possible heart injury. Participants will also undergo testing to assess sense of smell, cognition (thinking and memory), spirometry (breathing test for lung function) and and exercise tolerance (walk test). | N/A |
| PARAGON-B | Unstable Angina, Myocardial Infarction | Phase 3 | 1997 - 1998 | A randomized, double-blind, placebo-controlled study of lamifiban in patients with unstable angina/non-Q wave myocardial infarction. | N/A |
| PREMIER | Myocardial Infarction | Phase 3 | 2003 - 2004 | Premier is a phase lla proof of concept study that will explore the use of a matrix metalloproteinase (MMP) inhibitor in patients with left ventricular ejection fraction between 15% and 40% following a first ST elevation myocardial infarction | N/A |
| PROACT | NSTEMI | Chart Review | 2008 | N/A | |
| PROACT-2 | NSTEMI | Chart Review | 2010 | N/A | |
| PROACT-3 | NSTEMI | Phase 4 | 2011 - 2013 | Utilizing the platform of pre-hospital STEMI research and clinical experience developed over the past decade; we now intend to investigate how best to achieve timely diagnosis and risk stratification of patients that present to pre-hospital emergency medical services with symptoms suspicious for acute NSTEMI through utilization of systematic clinical assessment, pre-hospital 12 lead electrocardiogram and point of care measurement of biomarkers. Additionally, where deemed appropriate these patients will be enrolled in a clinical Chest Pain Protocol utilizing the pre-hospital biomarkers. We hypothesize that establishing a pre-hospital diagnosis in this condition may facilitate efficient triage and -as appropriate- in-hospital disposition. Additionally, the enhanced pre-hospital assessment of this population will facilitate appropriate timely disposition of those patients not found to have acute cardiovascular disease. These processes will facilitate decanting the frequently overcrowded and under resources Emergency Departments. | NCT01634425 |
| PROACT-4 | NSTEMI | Phase 4 | 2012 - 2015 | The purpose of this study is to determine if early diagnosis and risk stratification acquired through pre-hospital clinical assessment, 12-lead electrocardiogram and point of care biomarkers will facilitate enhanced triage and treatment in patients with presumed non-ST elevation acute coronary syndromes (NSTEMI). | NCT01634425 |
| PURSUIT | Myocardial Infarction | Phase 3 | 1995 - 1997 | A randomized, double blind Study of Integrelin, A Potent llb/llla Platelet Inhibitor, versus placebo in patients with unstable angina or Non-Qwave MI | N/A |
| RADAR | Acute Coronary Syndrome | Phase 2 | 2009 - 2011 | The purpose of this study is to evaluate the safety and efficacy of the REG1 anticoagulation System in Acute Coronary Syndrome (ACS) patients undergoing cardiac catheterization. | NCT00932100 |
| REGULATE-PCI | Coronary Artery Disease | Phase 3 | 2013 - 2014 | This study is designed to determine the efficacy of REG1 compared to bivalirudin in preventing periprocedural ischemic complications and major bleeding in patients undergoing PCI as a treatment for CAD. Bivalirudin has been studied in patients undergoing PCI in both ACS (NSTEMI and unstable angina [UA]) and elective PCI. In comparison to UFH, bivalirudin has shown similar rates of ischemic events while demonstrating a significant reduction in bleeding and an improved net clinical benefit. | NCT01848106 |
| SONOSTEMI-LYSIS | Acute Coronary Syndrome | Investigator Initiated | 2019 - 2024 | SONOSTEMI-LYSIS is an open label, single-centre, randomized investigation of sonothrombolysis in 60 adult patients presenting with STEMI within 6 hours of the onset of clinical symptoms and receiving perfusion therapy with fibrinolysis as part of a pharmacoinvasive strategy. | NCT04217304 |
| STABILITY | Atherosclerosis | Phase 3 | 2008 - 2013 | This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease. | NCT00799903 |
| STREAM | Acute Myocardial Infarction | Phase 3 | 2008 - 2012 | The purpose of this study is to assess the safety and efficacy of Enoxaparin and Unfractionated Heparin in St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention. | NCT00882635 |
| SYMPHONY | Acute Coronary Syndromes | Phase 3 | 1997 - 1998 | Sibrafiban Versus Asprin to yield Maximum Protection from Ischemic Heart Events Post Acute Coronary Syndromes | N/A |
| 2ND SYMPHONY | Acute Coronary Syndromes | Phase 3 | 1998 - 1999 | Randomized, double blind, asprin controlled trial that aims to evaluate the efficacy and safety of Xubix as therapy for the long term prevention of secondary events in patients after an acute coronary event | N/A |
| SYNERGY | Myocardial Infarction | Phase 3 | 2001 - 2003 | Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy | NCT00043784 |
| TECOS | Type 2 Diabetes Mellitus | Phase 3 | 2008 - 2015 | This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%.Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint. | NCT00790205 |
| TRACER | Atherosclerosis Myocardial Infarction Myocardial Ischemia | Phase 3 | 2007 - 2011 | The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional benefit over the existing standard of care in preventing heart attack and stroke. | NCT00527943 |
| TRILOGY ACS | Acute Coronary Syndrome | Phase 3 | 2008 - 2012 | This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization). | NCT00699998 |
| VALIANT | Myocardial Infarction | Phase 3 | 1998 | Phase lll, double blind, randomized, active controlled mortality trial with Valsartan versus Captopril | N/A |
| VITA-HF | Heart Failure | Phase 2 | 2012 - 2014 | Evaluate the efficacy and safety of testosterone supplementation on functional capacity, biomarkers, quality of life and clinical outcomes for patients with heart failure. | NCT01469988 |
| WATCH | Heart Failure | Phase 3 | 1998 - 2004 | Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics. Some authorities do not recommend anticoagulation for CHF patients in sinus rhythm, others recommend anticoagulation in patients with primary cardiomyopathy, and still others consider it more appropriate in patients with coronary artery disease (CAD). This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events). | NCT00007683 |
| WEST | Myocardial Infarction | Phase 2, Phase 3 | 2003 - 2005 | In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. | NCT00121446 |
| XANADU-ACS | Acute Coronary Syndrome | Phase llA | 2001 | Multi-centre, randomized, double-blind, double-dummy, heparin-controlled trial with recommended cardiac catheterization. | N/A |
| XANADU-PCI PILOT | Acute Coronary Syndrome | Phase 2 | 2000 - 2001 | A preliminary safety assessment and dose finding study of DX-9065a in patients scheduled for elective percutaneous coronary intervention | N/A |
